A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of the Oxyntomodulin Analog, LY2944876, in Healthy Japanese Subjects and Healthy Non-Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2015
Price : $35 *
At a glance
- Drugs Pegapamodutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 06 Jan 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 28 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 28 Oct 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.